Read the storyBlockbuster weight-loss drugs have transformed Novo Nordisk into Europe's most valuable company and an icon in its home country, Denmark. The drugmaker's meteoric rise has also been a boon for the economy, which would have stagnated last year without Novo's massive investments, expanding production and $2.3 billion corporate tax injection. But its enormous scale and influence also comes with risks for the company and country, making it particularly vulnerable to public backlash or regulatory shifts. CEO Lars Fruergaard Jorgensen says he's realistic about these delicate dynamics: "When you have superpowers, you have super responsibility." Read The Big Take. |
No comments:
Post a Comment